SCHEDULE 13G/A: Vanguard Group Discloses 8.3% Stake in Harmony Biosciences Holdings Inc.
Beneficial Ownership Report
The Vanguard Group has filed an amended Schedule 13G, revealing its beneficial ownership of 8.3% of Harmony Biosciences Holdings Inc.'s common stock as of December 31, 2024.
Summary
- The Vanguard Group reported beneficial ownership of 4,733,609 shares of Harmony Biosciences Holdings Inc. common stock.
- This holding represents an 8.3% stake in the company's common stock.
- As an investment adviser, The Vanguard Group holds these shares for its clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts.
- The Vanguard Group exercises sole dispositive power over 4,616,923 shares and shared dispositive power over 116,686 shares.
- The Vanguard Group holds no sole voting power but has shared voting power over 73,029 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing (Schedule 13G) disclosing beneficial ownership. It contains factual data about shareholdings and does not convey positive or negative sentiment regarding the issuer's performance or outlook.
Positives
- The disclosure of a significant institutional holding by The Vanguard Group, a major investment firm, may signal confidence in Harmony Biosciences Holdings Inc. to the market.
- Vanguard's role as an investment adviser holding shares for diverse clients indicates a broad base of indirect investment in Harmony Biosciences.
Future Outlook
NA
Industry Context
This filing reflects a routine disclosure by a large institutional investor, The Vanguard Group, regarding its passive ownership stake in Harmony Biosciences Holdings Inc. Such filings are common for major asset managers who hold diversified portfolios on behalf of their clients. It does not provide specific insights into Harmony Biosciences' operational performance or industry trends beyond confirming institutional interest.
Stakeholder Impact
- Shareholders: Existing shareholders may view Vanguard's significant stake as a positive signal of institutional confidence, potentially influencing market perception and liquidity.
- Investment Professionals: Provides updated information on institutional ownership, which is relevant for market analysis and tracking major holders.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement, representing the reporting period end date for beneficial ownership. |
| 01/30/2025 | Date the Schedule 13G/A Amendment No. 2 was signed by The Vanguard Group. |
Keywords
Harmony Biosciences Holdings Inc., Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Adviser, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.